Publications
In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD.. Brain Struct Funct.
.
2015. Measuring the impact of cognitive and psychosocial interventions in persons with mild cognitive impairment with a randomized single-blind controlled trial: rationale and design of the MEMO+ study.. Int Psychogeriatr. 27(3):511-25.
.
2015. Patterns of Cognitive Decline Prior to Dementia in Persons with Mild Cognitive Impairment.. J Alzheimers Dis. 47(4):901-13.
.
2015. Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.. Mol Psychiatry.
.
2016. Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease? Transl Neurodegener. 5:20.
.
2016. Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.. Can J Neurol Sci. 43(4):503-12.
.
2016. Defeating Alzheimer's disease and other dementias: a priority for European science and society.. Lancet Neurol. 15(5):455-532.
.
2016. Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase.. Alzheimers Dement. 12(1):75-84.
.
2016. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.. J Alzheimers Dis. 51(4):1237-47.
.
2016. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.. Lancet. 388(10062):2873-2884.
.
2016. Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients.. Continuum (Minneap Minn). 22(2 Dementia):615-8.
.
2016. Hippocampus and amygdala volumes from magnetic resonance images in children: Assessing accuracy of FreeSurfer and FSL against manual segmentation.. Neuroimage. 129:1-14.
.
2016. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.. Alzheimers Dement. 12(3):292-323.
.
2016. Selective familiarity deficits in otherwise cognitively intact aging individuals with genetic risk for Alzheimer's disease.. Alzheimers Dement (Amst). 2:132-9.
.
2016. VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis.. Front Neuroinform. 10:20.
.
2016. Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 12(1):60-4.
.
2016. [(18)F]FDG PET signal is driven by astroglial glutamate transport.. Nat Neurosci. 20(3):393-395.
.
2017. Application of calibrated fMRI in Alzheimer's disease.. Neuroimage Clin. 15:348-358.
.
2017. Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 89(18):1931.
.
2017. Brain perfusion during rapid-eye-movement sleep successfully identifies amnestic mild cognitive impairment.. Sleep Med. 34:134-140.
.
2017. Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer's disease.. Alzheimers Dement. 13(5):592-597.
.
2017. Familiarity deficits in cognitively normal aging individuals with APOE ε4: A follow-up investigation of medial temporal lobe structural correlates.. Alzheimers Dement (Amst). 9:21-24.
.
2017. Family history and APOE4 risk for Alzheimer's disease impact the neural correlates of episodic memory by early midlife.. Neuroimage Clin. 14:760-774.
.
2017. Identifying incipient dementia individuals using machine learning and amyloid imaging.. Neurobiol Aging. 59:80-90.
.
2017. The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations.. J Alzheimers Dis. 56(3):929-938.
.
2017.